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Abstract
Background: Capillary glucose (CG) measured with point-
of-care glucometers can provide useful approximation of 
plasma glucose (PG) in selected circumstances but the 
validity of measurements has been adequately assessed 
only for a few glucometers.
Methods: We assessed the difference between CG meas-
ured with a glucometer (Contour Ascensia, Bayer) and PG 
measured with a standard laboratory method in partici-
pants to a population-based cardiovascular survey in the 
Seychelles (sample size 1227).
Results: CG correlated well with PG (r = 0.94; p < 0.001). The 
overall difference between PG and CG was –0.55 mmol/L 
for PG  < 4.0  mmol/L (n = 19; 95% CI –0.92; –0.18); 
0.14  mmol/L for PG 4.0–4.9 (n = 344; 95% CI 0.08–0.20) 
and increased according to PG up to 1.64  mmol/L for 
PG  > 9.0 mmol/L (n = 68; 95% CI 1.36; 1.91). The prevalence 
of diabetes in the study sample was 29% lower with CG 
than with PG (8.6% vs. 12.1%) but this bias could be cor-
rected by analytical re-calibration.
Conclusions: CG underestimated PG, although the bias 
was small among persons with low glycemia. This sys-
tematic difference may bear little significance when the 
purpose is to simply monitor blood glucose but has large 
impact on prevalence estimates at the population level if 
CG values are not adequately calibrated.
Keywords:  Africa; capillary glucose; diabetes; epidemiol-
ogy;  plasma glucose; point-of-care testing; Seychelles.
Introduction
It is estimated that 382 million people had diabetes in 
2013, with a vast majority of them living in low- and mid-
dle-income countries, and the prevalence is expected to 
further rise in parallel with the increasing prevalence of 
obesity worldwide [1–3], including in Seychelles [4]. Dia-
betes is a main cause of cardiovascular disease, kidney 
failure, blindness, and other severe diseases [3, 5, 6]. Early 
treatment of diabetes can prevent or delay complications 
[2, 7–9], which emphasizes the need for early diagnosis 
and management of diabetes and pre-diabetes.
Fasting plasma glucose (PG)  ≥ 7.0 mmol/L (126 mg/dL), 
when confirmed, is a sufficient criterion for the diagnosis 
of diabetes [10, 11]. Lower levels of fasting blood glucose 
also increase the risk of several diseases [12]. Two cutoff 
values for pre-diabetes status are generally considered: 
fasting PG between 5.6 and 6.9 mmol/L for the  American 
Diabetes association (ADA) [10] and between 6.1 and 
6.9 mmol/L for the World Health Organization (WHO) and 
the International Diabetes Federation (IDF) [2, 11].
Cutoffs for the diagnosis of diabetes and pre-diabetes 
are based on fasting PG, which requires blood drawing. 
However, blood glucose can also be measured on capillary 
blood using point of care glucometers; these instruments 
revolutionized the treatment and management of diabe-
tes as they can be used in any setting, they are easy to 
operate, and they provide immediate results [3]. Measure-
ments of capillary glucose (CG) with glucometers are used 
for blood glucose monitoring at home or in the hospital 
among persons known to have diabetes [13, 14]. However, 
more studies are necessary to examine the validity of CG 
to predict diabetes, particularly the newer models which 
are smaller, faster and possibly better calibrated. There 
is a need to assess whether these glucometers could be 
used for screening purposes or in epidemiological surveys 
 [15–17], particularly in resource limited settings.
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Glucose measured on whole blood is 11% lower than 
glucose measured on venous plasma [11]. This is why the 
glucose cut off to define diabetes has been advised to be 
lower when measured on whole blood (6.1 mmol/L), for 
example with point of care glucometers, than when meas-
ured on plasma (7.0 mmol/L) [18]. However, most current 
glucometers, including the Contour Ascensia used in this 
study, automatically adjust glucose results from capil-
lary whole blood to equivalent PG values by means of an 
electronic algorithm built in the glucometer. Therefore, 
CG readings with modern glucometers are expected to be 
equal to PG values. However, the automatic calibration 
by glucometers remains a challenge as accuracy must 
apply throughout the entire range of glycemia. Accuracy 
of this calibration cannot be implied from a particular glu-
cometer to another model as calibration is a proprietary 
inbuilt process in the glucometer. Therefore, every differ-
ent brand and model of glucometer should be assessed 
separately. Furthermore, it remains useful to evaluate the 
accuracy of calibration of a particular glucometer in the 
different populations in which the glucometer is used [19], 
as factors influencing glycemia may differ across popula-
tions, e.g. the prevalence of anemia in the population. 
Apart from this technical difference, CG may differ from 
venous glucose according to nutritional or other factors 
[11, 19].
Some epidemiological studies have used glucome-
ters to assess diabetes in low resource settings because 
of convenience and low cost [20–24]. When facing 
limited resources, the argument can be made that it 
is better to assess diabetes status using a glucometer 
than not measuring glucose at all [23]. However, not all 
of these studies have adjusted their findings on diabe-
tes prevalence to the bias between CG and PG and/or 
conducted validation studies within these surveys in 
order to possibly recalibrate their results according to 
standard PG measurements. Because assessing diabe-
tes using CG measured with glucometers may be useful 
in some situations (particularly in low resources coun-
tries), there is a need for manufacturers to continuously 
improve the calibration of their glucometers and for 
investigators to assess the accuracy of glucometers they 
are using [17].
In this study, we compared CG measured with the 
Contour glucometer (Bayer) with PG measured with a 
standard laboratory method in the participants to a pop-
ulation-based cardiovascular survey in the Seychelles 
who underwent both measurements at the same time. We 
examined the differences in the prevalence of diabetes 
and pre-diabetes based on measurements with CG and 
PG, including after analytical recalibration of CG to PG.
Materials and methods
Data came from a national population-based cardiovascular sur-
vey conducted in the Seychelles in October–December 2013 and in 
 February 2014 (Seychelles Heart Survey IV). Methods and overall 
results were previously described [25]. The survey was conducted on 
a sex and age random sample of the whole population aged 25–64 
and was attended by 1240 participants (participation rate: 73%). 
 Eligible participants were invited to attend a study center between 
6:30 and 10:00 am on a given date and they were requested to be 
fasting when they attended. Within 10–30  min after arrival to the 
study center, venous blood and capillary blood was collected within 
an interval of 2 min. Measurement on CG was done immediately 
with an Ascensia Contour glucometer (Bayer Consumer Care, Basel, 
 Switzerland). Venous blood was collected using standard 2.5  mL 
tubes containing sodium fluoride and potassium oxalate to prevent 
glucolysis (BD, Plymouth, UK) and glucose was measured at the 
laboratory of the main hospital of Seychelles within 2–3 h of blood 
collection with an automatic analyzer ( Konelab 30i, Thermo, Vanta, 
Finland) with reagents from the same company. The procedure used 
glucose oxydase (GOD) and a modified Trinder color reaction cata-
lyzed by the enzyme peroxydase (POD). The imprecision (CV) for the 
GOD-POD glucose assay using a Konelab analyzer varies according to 
the mean glucose level but is CV  < 3% overall according to the notice 
of the manufacturer. The Ascensia Contour glucometer measures glu-
cose levels using glucose dehydrogenase (GDH) flavin dinucleotide 
(FAD) chemistry, with no interference from maltose or galactose. The 
CV of the Contour glucometer is  < 5% according to the notice of the 
manufacturer. Glucose measurements were available for both PG and 
CG in 1227 participants from a total of 1240 participants and analyses 
in this study are therefore limited to these 1227  participants.
Our research met the ethical guidelines, including adherence 
to the legal requirements of the study country.
We examined the difference between PG and CG according to 
different PG categories. We analytically removed the overall bias 
between CG and PG by transforming CG values into “corrected” CG 
values (cCG) using the linear regression equation CG = 0.83 PG+0.51. 
We estimated the prevalence of diabetes based on PG and CG before 
and after analytical re-calibration of the glucometer results. We 
examined the sensitivity, specificity, positive predictive value and 
negative predictive value of CG to predict PG, without and with ana-
lytical recalibration, assuming that PG was the gold standard. We 
computed the discordance rate (DR) between the estimated preva-
lence of diabetes or pre-diabetes based on either PG or CG measure-
ments. DR is an indicator of diagnosis misclassification: it represents 
the sums of positive and negative discordance values in percent (i.e. 
the probability of discordant decisions between PG and CG). As this 
is a validity study comparing blood glucose measured along two dif-
ferent methods, prevalence estimates were calculated in the current 
sample and are not weighted for the distribution of the actual popu-
lation or for some other standard population distribution.  Statistical 
analysis was performed with Stata 11.2.
Results
Figure 1 shows the association between PG and CG meas-
urements; the correlation coefficient between CG and PG 
was high (r = 0.94; p < 0.001). Overall, CG underestimated 
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PG (i.e. 5.41±1.92  mmol/L vs. 5.91±2.18 mmol/L, respec-
tively), but it can be seen that the difference between 
PG and CG underestimates increases with increasing PG 
values.
Figure 2 shows the systematic difference (i.e. the bias) 
between PG and CG according to PG. It can be seen that 
there is large variability in the differences between CG and 
PG between individuals at any level of PG, and that the 
systematic difference between PG and FG is minimal at 
low PG values but increases monotonically along higher 
PG values.
Figure 1: Relation between plasma glucose and capillary glucose, 
and linear trend.
Figure 2: Difference between plasma glucose and capillary glucose 
according to plasma glucose and linear trend.
Table 1: Difference between plasma glucose (PG) and capillary 
glucose CG) and discordance rate according to categories of plasma 
glucose.
Plasma 
glucose, 
mmol/L
  n   Difference, 
PG minus 
CG
  95% CI   Discordance 
rate, DR
Total sample  1227   0.50   0.46; 0.54   4.0
 < 4.0   19   –0.55   –0.92; –0.18   0
4.0–4.9   344   0.14   0.08; 0.20   0
5.0–5.9   545   0.51   0.47; 0.55   0
6.0–6.9   170   0.69   0.59; 0.78   1.8
7.0–7.9   46   0.67   0.42; 0.92   76.1
8.0–8.9   35   1.17   0.80; 1.54   31.4
 ≥ 9.0   68   1.64   1.36; 1.91   0
Table 1 quantifies the mean difference between PG 
and CG according to selected PG categories. The dif-
ference is negative at PG values lower than 4 mmol/L, 
minimal at PG of 4-5 mmol/L, and increasingly large 
at higher PG values. Overall, CG was lower than PG by 
0.50±0.75 mmol/L (95%CI: 0.46 to 0.54), i.e. CG was 8.5% 
lower than PG. Table 1 also shows that the discordance 
rate was 4% overall but increased around the cutoff point 
for diabetes diagnosis (i.e. DR 76% for PG = 7–8 mmol/L).
Table 2 shows the concordance between categories 
of PG and CG. The kappa statistic was fair (κ = 0.79 before 
and κ = 0.80 after analytical recalibration of CG). The Table 
also emphasizes the large variability between CG and PG, 
i.e. a substantial number of persons had high CG and low 
PG, and vice versa.
Table 3 shows the impact arising from the system-
atic difference between the two methods. The prevalence 
of diabetes (i.e. glucose  ≥ 7.0 mmol/L) in the sample of 
participants was lower by 29% based on CG, i.e. 8.6% 
(95% CI: 7.1–10.2) with CG and 12.1% (95% CI: 10.3–14.0) 
with PG. When using the cut-off of  ≥ 6.1 mmol/L to define 
diabetes on whole blood as suggested by the WHO in 
1999 [16], the prevalence of diabetes was 16.2% (95% CI: 
14.2–18.3), i.e. 34% higher than with PG. When consid-
ering pre-diabetes according to the ADA (i.e. FPG  ≥ 5.6) 
the prevalence based on CG was 36% lower than based 
on PG. Upon analytic re-calibration of CG to PG using 
linear regression, the prevalence of diabetes was similar 
with calibrated CG (cCG) and PG. Since CG underesti-
mates PG overall, the positive predictive value (PPV) of 
CG  ≥ 7.0  mmol/L to identify PG  ≥ 7.0  mmol/L was high 
(97.2%), but PPV decreased to 80.5% upon analytical 
recalibration. The negative predictive value of low CG to 
identify low PG was fairly high ( > 95%) for both CG and 
cCG, largely because the prevalence of diabetes is low in 
this healthy population sample.
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Table 2: Concordance between categories of capillary glucose and plasma glucose.
Plasma glucose, 
mmol/L
Capillary glucose, mmol/L
 < 4.0   4.0–4.9   5.0–5.9   6.0–6.9   7.0–7.9   8.0–8.9    ≥ 9.0
 < 4.0   6   11   2   0   0   0   0
4.0–4.9   64   198   80   2   0   0   0
5.0–5.9   18   275   235   17   0   0   0
6.0–6.9   0   20   100   47   3   0   0
7.0–7.9   0   1   4   30   9   1   1
8.0–8.9   0   1   4   6   18   5   1
 ≥ 9.0   0   0   0   0   6   12   50
Table 3: Prevalence of elevated blood glucose and validity indices of capillary glucose to predict elevated readings, assuming that plasma 
glucose is the gold standard, before and after recalibration using a linear regression.
 
 
Diabetes, 
 ≥ 7.0 mmol/L
 
 
Impaired fasting glucose or diabetes, 
 ≥ 5.6 mmol/L
Plasma 
glucose
  Capillary 
glucose
  Calibrated 
CGa
Plasma 
glucose
  Capillary 
glucose
  Calibrated 
CGa
Prevalence, %   12.1   8.6   13.0   40.4   26.0   43.4
95%CI, %   10.3; 14.0   7.0; 10.2   11.1; 14.8   37.7; 43.2   23.5; 28.5   40.6; 46.1
Discordance rate, %     4.0   4.2     21.1   23.0
Sensitivity, %     69.1   85.9     56.0   75.2
Specificity, %     99.7   97.1     94.0   78.2
Positive predictive value, %     97.2   80.5     87.0   70.1
Negative predictive value, %     95.9   98.0     76.0   82.3
aRe-calibration was obtained by transforming each measurement of CG with a linear function obtained from linear regression.
3.7% 8.4%
0.2%
10.4%
2.5%1.7%
Without calibration With calibration
Figure 3: Prevalence of glucose  ≥ 7 mmol/L in the study sample 
based on plasma glucose (blue circle) or capillary glucose (red 
circle), without and with analytical calibration of capillary glucose to 
plasma values.
Figure 3 shows the concordance between the preva-
lence of diabetes based on PG, CG and cCG. The overall 
prevalence of diabetes was similar with cCG and PG, but 
a substantial proportion of persons identified as diabetic 
based on cCG were not identified as diabetic based on PG 
(i.e. there was a substantial number of false positive cases 
of diabetes identified with cCG, assuming that PG is the 
gold standard).
Discussion
We found that the difference between CG and PG was 
minimal at low blood glucose levels but increased monot-
onically according to increasing glucose values. With an 
overall bias between PG and CG of 8.5% (0.50 mmol/L), 
the glucometer used in our study does not comply with 
the Laboratory Medicine Practice Guidelines from the 
National Academy of Clinical Biochemistry of the Ameri-
can Association for Clinical Chemistry, which recommend 
that the bias of an instrument should be lower than 2.2% 
to be suitable for the diagnosis of diabetes [16]. This sys-
tematic difference between CG and PG, which is clinically 
not large, may bear little significance when the purpose 
is to monitor blood glucose in diabetic patients. However, 
the difference has large impact when the purpose is to 
diagnose diabetes or to assess the prevalence of diabetes 
in the population.
Other studies on different glucometers have generally 
reached similar conclusions as our study. A study made 
in 2003 on eight different glucometers found that the bias 
between CG and PG varied between 0.14% and 16.9% [26]. 
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Two recent studies have been made on glucomenters in 
2012 and 2014 in which the Contour glucometer did not 
fulfill the new accuracy performance criteria of the new 
ISO15197 guideline [27, 28]. Factors related to the lack of 
accuracy of glucometers include a low hematocrit, inter-
ferences with other substances [7], nutritional state of 
the patient, or inaccurate calibration of the glucometer 
to convert a CG value to an equivalent PG reading. Other 
patients’ characteristics can also play a role. For example 
CG may be lower than PG in a fasting patient but CG may 
be higher than PG in non-fasting patients [11, 19]. It is also 
known that there is a bigger difference between arterial 
blood glucose and venous blood glucose when the blood 
glucose is high as when the blood glucose is low. This 
explains why the bias increases according to increasing 
glucose values. Blood glucose deducted from conversion 
from CG to equivalent value of PG, or vice-versa, has been 
typically associated with a bias of at least 0.5 mmol/L [19, 
29]. It could however, be argued that algorithms of calibra-
tion of glucometers could be further improved to provide 
readings that actually are equal, or closer, to plasma 
values along the whole range of blood glucose in most 
populations.
In this study, the discordance rate to classify persons 
as having glucose  ≥ 7.0  mmol/L (diabetes) or not, using 
either CG or PG, is  < 5%, meaning that more than 95% 
of all subjects in our population-based sample are con-
cordantly classified. This fairly low discordance rate is 
largely explained by the facts that only a small number 
of persons have glucose  ≥ 7.0 mmol/L (around 10%) and a 
substantial proportion of participants have low PG, i.e. a 
range where there was only little bias between FG and PG. 
However, and as expected, the discordance rate is greater 
when the glucose cutoff to discriminate between high and 
low glucose is lowered (e.g. blood glucose  ≥ 5.6 mmol/L, 
which defines prediabetes according to the ADA) and more 
persons subsequently fall into the upper glucose category. 
Validity indicators such as the discordance rate, the posi-
tive predictive value or the negative predictive value all 
depend on the prevalence of the condition being screened 
so that findings in our study may not be automatically 
generalized to other populations. However, our findings 
suggest that a low CG value has a high negative predictive 
value to exclude the presence of diabetes; a high CG value 
has a high positive predictive value to identify diabetes, 
but intermediate CG values should be rechecked on PG 
with a standard laboratory method.
WHO guidelines in 1999 advised to use a cutoff of 
6.1 mmol/L when assessing diabetes based on whole blood 
glucose [18]. At this time, glucometers, which measure 
glucose on whole blood, were not adjusted to display 
glucose readings that are equivalent to PG values. Our 
results show that the prevalence of diabetes was largely 
overestimated using this whole blood cutoff of 6.1 mmol/L 
with the Contour Ascensia, but largely underestimated 
using the PG cutoff of 7.0 mmol/L with the same glucom-
eter. Current glucometers are expected to provide whole 
blood CG readings that are adjusted to PG equivalents. 
Yet, we found that neither the 7.0 mmol/L cut off nor the 
6.1 mmol/L cut off accurately assessed the prevalence of 
diabetes in our population. However, in view of the pos-
sibility that diabetes may be assessed with glucometers 
in some resource limited settings, guidelines on the use 
of glucometers to assess diabetes in selected situations 
should be updated.
It has been proposed that CG measured with a glu-
cometer may be useful to assess the prevalence of diabe-
tes in populations in particular situations, e.g. in resource 
limited settings [15, 16]. However, the substantial system-
atic difference between CG and PG at blood glucose levels 
close to the cutoff values for the diagnosis of diabetes 
resulted in a large bias in estimating the prevalence in 
our study sample (8.6% with CG vs. 12.8% with PG). This 
underlines the need to analytically re-calibrate results 
yielded with glucometers used for this epidemiological 
purpose. A few strategies have been proposed to over-
come the challenge of systematic differences between 
CG and equivalent PG. First some new glucometers can 
measure a person’s hematocrit and adjust glucose read-
ings accordingly so that the bias between PG and FG 
may be avoided [30]. Second, the bias between PG and 
CG can be assessed in a sub-sample of the population in 
which the prevalence of diabetes is being assessed, and 
CG values can then be analytically recalibrated to PG 
readings [19]. Third if no calibration of CG to PG is per-
formed, a two-step strategy can be used to identify dia-
betic persons by performing CG in all participants and 
re-check blood glucose in those individuals who have CG 
in the intermediate range (e.g. 6–7 mmol/L) using PG and 
a standard laboratory method [31].
Irrespective of a bias between CG and PG, we found 
important variability between readings with CG and PG at 
the individual level: substantial numbers of persons had 
high glucose values with CG but low values with PG, and 
vice versa. Variability in glucose readings can arise from 
both CG and PG measurements. Because we used only 
one glucose measurement in each individual with either 
method, we cannot assess the magnitude of the variability 
in glucose readings with either method. Of note, variabil-
ity of CG and PG measurements at the individual level does 
not bias the point estimates of mean glucose or prevalence 
of diabetes in the whole population, but it does widen the 
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95% confidence intervals around these point estimates. 
Variability in glucose measurements implies that meas-
urements (CG or PG) should be measured on several dif-
ferent occasions in a same individual when results need 
to be accurate at the individual level (e.g. when assessing 
the presence of diabetes in a particular individual).
There are several limitations to this study. First, we 
did not repeat measurements of CG and PG and we were 
therefore unable to assess the variability in glucose read-
ings with either method. However, variability at the indi-
vidual level does not alter point estimates of mean levels 
or prevalence in the population. Second, when comput-
ing validity indices (e.g. the predictive value of high CG to 
identify high PG), we assumed that the laboratory method 
(PG) was the gold standard. However, the laboratory 
method is also subject to variability and bias. Although 
quality control on PG was performed every day in our clin-
ical laboratory, we did not cross check our PG values in 
this study with measurements made in an established ref-
erence laboratory. Third, tubes used to collect plasma for 
glucose measurement had sodium fluoride and potassium 
oxalate added as a glycolysis inhibitor. However, sodium 
fluoride and potassium oxalate fully prevent glycolysis 
only after 2–3 h. This may lead to some underestimation of 
venous PG. Fourth some participants may not have been 
fasting which can influence the relation between FG and 
CG [19]. Fifth, our goal was to compare CG and PG, and 
the impact of the bias between CG and PG on the preva-
lence estimate of diabetes in the population, but not to 
assess the true prevalence of diabetes in the population. 
The definite diagnosis of diabetes should rely on unbiased 
glucose measurement, repeat blood glucose measure-
ments, and may also include criteria that we did not use 
in this study, such as oral glucose tolerance test (OGTT) or 
HbA1c [32]. Sixth, we could not adjust results to different 
factors that may influence CG or PG, such as hematocrit 
or blood levels of proteins, maltose or immunoglobulins. 
On the other hand, strong points of our study are the large 
sample size, the population based nature of the sample, 
the standard methods used, and the fact that we assessed 
the difference between CG and PG in different categories 
of blood glucose.
Conclusions
Our findings generally support current recommendations 
on the use of point of care glucometers. The fairly good cor-
relation between CG and PG supports the use of simple, 
quick and inexpensive measurement of CG with a glucome-
ter when the purpose is to monitor blood glucose in patients 
known to have diabetes or in other specific situations 
where approximate values are sufficiently informative. 
However, the use of PG and standard laboratory methods 
remains essential when the purpose is to identify diabetes 
or pre-diabetes. While low CG values strongly suggest the 
absence of diabetes and high CG values strongly suggest 
the presence of diabetes, intermediate CG values need to 
be re-checked with PG and standard laboratory methods. 
From an epidemiological perspective, any systematic dif-
ference between CG and PG will result in a biased point 
estimate of the prevalence of diabetes in the population. 
Therefore, glucometers used in epidemiological surveys 
should be calibrated accordingly (e.g. by measuring CG 
and PG in a sub-sample of the survey participants and 
adjusting CG to be equal to PG values) or using alternate 
strategies (e.g. recheck glucose with PG in persons who 
have intermediate CG values). More generally, there is a 
need for more comprehensive information from manufac-
turers on the validity of glucometers. Further sufficiently 
powered studies need to be conducted in different popu-
lations to assess the validity of glucometers available in 
the market. In view of better performance of current than 
past glucometers, guidelines on the significance of glucose 
readings with glucometers should be updated.
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